The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Attamage-A1: Phase I/II study of autologous CD8+ and CD4+ transgenic t cells expressing high affinity MAGE-A1-specific T-cell receptor (TCR) combined with anti-PD(L)1 in patients with metastatic MAGE-A1 expressing cancer.
 
Michael Thomas Schweizer
Consulting or Advisory Role - AstraZeneca; PharmaIn; Resverlogix
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); ElevateBio (Inst); Immunomedics (Inst); Immunomedics (Inst); Janssen (Inst); Madison Vaccines, Inc. (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Tmunity Therapeutics, Inc. (Inst); Zenith Epigenetics (Inst)
 
Ted Gooley
Consulting or Advisory Role - Kiadis Pharma; Pharmacyclics; Regimmune
 
Sylvia Lee
Patents, Royalties, Other Intellectual Property - Patent for BRAF-specific TCR, licensed to Lyell Immunopharma.
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
William R Gwin
Consulting or Advisory Role - CoreA Therapeutics
Research Funding - Veana Therapeutics
 
Monica Dherin
No Relationships to Disclose
 
Megan Hickner
No Relationships to Disclose
 
Jennifer Casserd
No Relationships to Disclose
 
Megan McAfee
No Relationships to Disclose
 
Thomas Schmitt
Stock and Other Ownership Interests - Affini-T Therapeutics; SignalOne Bio
Consulting or Advisory Role - Affini-T Therapeutics; SignalOne Bio
Research Funding - Affini-T Therapeutics; Cullinan Oncology; Lonza; SignalOne Bio
Patents, Royalties, Other Intellectual Property - licensing distributions through my institution from IP licensed to affini-T Therapeutics; licensing distributions through my institution from IP licensed to Cullinan Oncology; licensing distributions through my institution from IP licensed to Lonza
 
Cecilia CS Yeung
Consulting or Advisory Role - Loxo/Lilly; Merck; TwinStrand Biosciences
Research Funding - OBI Pharma; Pfizer
 
Vijayakrishna K. Gadi
Leadership - SEngine Precision Medicine
Stock and Other Ownership Interests - 3rdEyeBio; New Equilibrium Biosciences; Novilla; Sengine precision medicine
Consulting or Advisory Role - Novartis; Puma Biotechnology; Sanofi; Seagen
Speakers' Bureau - bioTheranostics; Seagen
Research Funding - Agendia; Genentech/Roche (Inst); SignalOne Bio
Travel, Accommodations, Expenses - Novartis
 
Aude Chapuis
Stock and Other Ownership Interests - Adaptive Biotechnologies; Affini-T Therapeutics; Karkinos Healthcare; SignalOne Bio; TScan Therapeutics
Consulting or Advisory Role - SignalOne Bio; TScan Therapeutics
Research Funding - Bluebird Bio; Lonza; SignalOne Bio
Patents, Royalties, Other Intellectual Property - Adaptive Biotechnologies; Bluebird Bio; Cullinan Oncology; Lonza; Pfizer